Eli Lilly Announces $1.4 Billion Settlement of Zyprexa Off-Label Claims

INDIANAPOLIS - Eli Lilly & Co. announced Jan. 15 that it would pay approximately $1.4 billion to settle allegations that it marketed the drug Zyprexa for unapproved uses, including the treatment of dementia in elderly patients.

The settlement ends a nearly five-year investigation by the federal government and civil claims brought against Eli Lilly in several states for the company's off-label promotion of Zyprexa, which is approved to treat schizophrenia. As part of the deal, Lilly will also plead guilty to one misdemeanor violation of the Food, Drug and Cosmetic Act, the company says.

According to a statement, the misdemeanor …